Literature DB >> 29982402

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

E Kastritis1, V Leblond2, M A Dimopoulos1, E Kimby3, P Staber4, M J Kersten5,6, A Tedeschi7, C Buske8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29982402     DOI： 10.1093/annonc/mdy146

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  19 in total

1.  Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline.

Authors:  Karima Amaador; Marie José Kersten; Monique C Minnema; Josephine M I Vos
Journal:  Hemasphere       Date:  2022-07-05

2.  Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.

Authors:  Cécile Tomowiak; Stéphanie Poulain; Charles Herbaux; Aurore Perrot; Béatrice Mahé; Pierre Morel; Thérèse Aurran; Olivier Tournilhac; Stéphane Leprêtre; Souad Assaad; Bruno Villemagne; Olivier Casasnovas; Delphine Nollet; Damien Roos-Weil; Sylvie Chevret; Véronique Leblond
Journal:  Blood Adv       Date:  2021-05-11

3.  MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation.

Authors:  Martina Ferrante; Daniela Furlan; Silvia Zibellini; Michela Borriero; Chiara Candido; Nora Sahnane; Silvia Uccella; Elisa Genuardi; Beatrice Alessandria; Benedetta Bianchi; Barbara Mora; Daniele Grimaldi; Irene Defrancesco; Cristina Jiménez; Federica Cavallo; Dario Ferrero; Irene Dogliotti; Michele Merli; Marzia Varettoni; Simone Ferrero; Daniela Drandi
Journal:  Diagnostics (Basel)       Date:  2021-04-26

4.  Treatment options for relapsed Waldenström's Macroglobulinemia.

Authors:  Alexander Grunenberg; Christian Buske
Journal:  Hemasphere       Date:  2019-06-30

5.  Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.

Authors:  Simona Elba; Alessia Castellino; Roberto Soriasio; Claudia Castellino; Margherita Bonferroni; Daniele Mattei; Giuliana Strola; Daniela Drandi; Nicola Mordini; Miriam Foglietta; Davide Rapezzi; Ivana Celeghini; Mariella Grasso; Fabrizio Giordano; Giulio Fraternali Orcioni; Massimo Massaia
Journal:  J Med Case Rep       Date:  2020-06-22

6.  Chylothorax as an Initial Manifestation of Waldenström macroglobulinemia.

Authors:  Natalia Rodriguez Botero; Andres Zerrate Misas; Kenny Mauricio Galvez Cardenas; Juan David Ramirez Quintero
Journal:  Cureus       Date:  2020-04-06

Review 7.  Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.

Authors:  Francesco Piazza; Veronica Di Paolo; Greta Scapinello; Sabrina Manni; Livio Trentin; Luigi Quintieri
Journal:  Front Oncol       Date:  2022-01-11       Impact factor: 6.244

8.  Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.

Authors:  Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Br J Haematol       Date:  2020-02-23       Impact factor: 8.615

9.  Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.

Authors:  Sara Rodriguez; Jon Celay; Ibai Goicoechea; Cristina Jimenez; Cirino Botta; Maria-José Garcia-Barchino; Juan-Jose Garces; Marta Larrayoz; Susana Santos; Diego Alignani; Amaia Vilas-Zornoza; Cristina Perez; Sonia Garate; Sarai Sarvide; Aitziber Lopez; Hans-Christian Reinhardt; Yolanda R Carrasco; Isidro Sanchez-Garcia; Maria-Jose Larrayoz; Maria-Jose Calasanz; Carlos Panizo; Felipe Prosper; Jose-Maria Lamo-Espinosa; Marina Motta; Alessandra Tucci; Antonio Sacco; Massimo Gentile; Sara Duarte; Helena Vitoria; Catarina Geraldes; Artur Paiva; Noemi Puig; Ramon Garcia-Sanz; Aldo M Roccaro; Gema Fuerte; Jesus F San Miguel; Jose-Angel Martinez-Climent; Bruno Paiva
Journal:  Sci Adv       Date:  2022-01-19       Impact factor: 14.136

10.  Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study.

Authors:  Simon Rule; Wolney Gois Barreto; Javier Briones; Angelo M Carella; Olivier Casasnovas; Chris Pocock; Clemens-Martin Wendtner; Francesco Zaja; Susan Robson; Lachlan MacGregor; Roger R Tschopp; Sonja Nick; Martin Dreyling
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.